Guideline‑Directed Medical Therapy for Post‑MI Heart Failure with Reduced Ejection Fraction

Foundational Pharmacologic Therapy

Four core drug classes (ACE inhibitor or ARB, evidence‑based β‑blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor) are required for all patients with LVEF < 40 % after myocardial infarction; this regimen reduces mortality and HF hospitalization. – Class I, Level A (American College of Cardiology) [1][2]
ACE inhibitors should be started within the first 24 h of presentation and continued indefinitely for every post‑MI patient with LVEF < 40 %. – Class I, Level A (American College of Cardiology) [3][4]5
Evidence‑based β‑blockers (carvedilol, metoprolol succinate, or bisoprolol) must be initiated immediately and continued indefinitely; these agents have proven mortality benefit in this population. – Class I, Level A (American College of Cardiology) [3][4][6][5]
Mineralocorticoid receptor antagonists (spironolactone or eplerenone) are indicated for all post‑MI patients with LVEF < 40 % who have diabetes or HF symptoms and are already on therapeutic ACE‑inhibitor and β‑blocker doses. – Class I, Level A (American College of Cardiology) [3][4]5
SGLT2 inhibitors (dapagliflozin or empagliflozin) are now part of foundational GDMT for HFrEF and should be started regardless of diabetes status. – Class I (American College of Cardiology) [1][2]

Initiation Timing and Dosing

ACE inhibitor target doses (e.g., enalapril 10 mg BID, ramipril 10 mg daily, lisinopril 10 mg daily) should be titrated to the levels used in clinical trials over 4–6 weeks. – Class I, Level A (American College of Cardiology) [3][4]
β‑blocker target heart rate is 55–60 bpm at rest; doses should be uptitrated every 2 weeks as tolerated to trial‑based target doses. – Class I, Level A (American College of Cardiology) 5
Mineralocorticoid receptor antagonists should be added within the first week after MI, provided renal function and potassium are acceptable. – Class I, Level A (American College of Cardiology) [3][4]
SGLT2 inhibitors can be initiated at any time after stabilization; they are recommended as soon as possible because they confer mortality and hospitalization benefits. – Class I (American College of Cardiology) [1][2]

Monitoring, Targets, and Duration

Renal function (creatinine/eGFR) and serum potassium must be checked 1–2 weeks after starting or up‑titrating ACE inhibitors or MRAs; therapy is contraindicated if creatinine > 2.5 mg/dL (men) or > 2.0 mg/dL (women) or potassium > 5.0 mEq/L. – Class I, Level A (American College of Cardiology) [3][4]
β‑blockers should be continued for a minimum of 3 years and preferably indefinitely in post‑MI HFrEF. – Class I, Level A (American College of Cardiology) [3][4]7

Contraindications and Switching Strategies

If a patient develops persistent cough, angioedema, or allergic reaction to an ACE inhibitor, switch immediately to an ARB (valsartan, candesartan, or losartan); ARBs are reserved exclusively for documented ACE‑inhibitor intolerance. – Class I, Level A (American College of Cardiology) [3][4]
Routine combination of ACE inhibitors with ARBs is discouraged because it raises the risk of hyperkalaemia and renal insufficiency without clear mortality benefit. – Class IIb (American College of Cardiology) [3][4]
Switching from ACE inhibitor or ARB to the ARNI sacubitril/valsartan is recommended for patients who remain symptomatic despite optimal GDMT, after a 36‑hour washout from ACE inhibitor. – Class I (American College of Cardiology) [1][2]
Severe bradycardia (HR < 50 bpm) is a contraindication to β‑blocker therapy. – Class I, Level A (American College of Cardiology) 5
Severe hyperkalaemia (K⁺ > 5.5 mEq/L) contraindicates ACE inhibitor or ARB use. – Class I, Level A (American College of Cardiology) [3][4]

Additional Evidence‑Based Therapies

Dual antiplatelet therapy (aspirin 75–100 mg plus a P2Y12 inhibitor) should be continued for 12 months after MI when PCI was performed, then transition to aspirin alone. – Class I, Level A (American College of Cardiology) 5
High‑intensity statin therapy should be started immediately and continued indefinitely, aiming for LDL‑C < 70 mg/dL (1.8 mmol/L). – Class I, Level A (American College of Cardiology) 5
All post‑MI patients should be referred to comprehensive cardiac rehabilitation before hospital discharge or at the first outpatient visit. – Class I, Level A (American College of Cardiology) [3][4]

Common Pitfalls to Avoid

Using β‑blockers other than carvedilol, metoprolol succinate, or bisoprolol is not evidence‑based and does not confer the proven mortality benefit. – Class I, Level A (American College of Cardiology) [3][4]6
Delaying initiation of mineralocorticoid receptor antagonists beyond the first week reduces the opportunity for early mortality benefit. – Class I, Level A (American College of Cardiology) [3][4]
Omitting SGLT2 inhibitors from the regimen overlooks a foundational therapy that improves outcomes in HFrEF regardless of diabetes status. – Class I (American College of Cardiology) [1][2]

Management of Post-Acute Coronary Syndrome

Introduction to Guideline Recommendations

The American Heart Association recommends that ACE inhibitors (ACEIs) should be started and continued indefinitely in all post-acute coronary syndrome patients with left ventricular ejection fraction (LVEF) <40%, heart failure, hypertension, diabetes, or chronic kidney disease 8, 9, 10
The European Society of Cardiology suggests that Angiotensin II Receptor Antagonists (ARAs) are reserved exclusively for patients with documented intolerance to ACEIs 8, 9, 10

Patient Evaluation and Treatment Initiation

For patients with LVEF <40%, ACEIs should be initiated immediately (within the first 24 hours if possible) and continued indefinitely, using proven effective doses (enalapril, ramipril, captopril, trandolapril) 8, 9, 10
In patients with LVEF 40-49% or ≥50%, ACEIs should be initiated if there is hypertension, diabetes, or chronic kidney disease 8, 9, 10

Management of Intolerance to ACEIs

If a patient develops persistent cough, angioedema, or allergic reactions, they should be switched to an ARA (losartan, valsartan, candesartan) 8, 9, 10
This is a Class I, Level of Evidence A recommendation for patients with LVEF <40% or heart failure 8, 9, 10

Consideration of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs)

ARNIs are not used in the acute post-coronary syndrome context but are considered for chronic heart failure with LVEF ≤40% and symptoms despite optimal therapy with ACEIs or ARAs 11

Monitoring and Dose Titration

Patients should be monitored for blood pressure, renal function, and potassium levels 1-2 weeks after initiating or increasing ACEI dose 8, 11
ACEIs should be titrated to target doses used in clinical trials (e.g., enalapril 10 mg twice daily, ramipril 10 mg/day) 8

Common Errors to Avoid

Not initiating ACEIs due to fear of adverse effects, as the risk of non-treatment far outweighs the risk of adverse effects 8
Using ARAs as first-line treatment instead of reserving them for true intolerance to ACEIs 8, 9, 10
Combining ACEIs and ARAs routinely, as this increases the risk of hyperkalemia and renal insufficiency without clear benefit in mortality 8
Initiating ARNIs in the acute post-coronary syndrome phase, as they are exclusively for chronic heart failure 11
Not titrating ACEIs to target doses, losing therapeutic benefit 8, 11

Post‑CABG Pharmacologic Management: ACE‑Inhibitor and Beta‑Blocker Recommendations

ACE‑Inhibitor Initiation

In patients who have undergone coronary artery bypass grafting, initiate an ACE inhibitor within 24 hours of surgery (if hemodynamically stable) and continue indefinitely; this is a Class I, Level A recommendation for all post‑CABG patients with any degree of left‑ventricular dysfunction or heart‑failure symptoms. [12][13]

Beta‑Blocker Initiation

Add an evidence‑based beta‑blocker (e.g., carvedilol, metoprolol succinate, or bisoprolol) immediately after surgery and maintain therapy long‑term; beta‑blockade is mandatory for all post‑CABG patients with left‑ventricular dysfunction. [12][13]

Avoidance of Inappropriate Sacubitril/Valsartan Use

Do not prescribe sacubitril/valsartan as first‑line therapy in post‑CABG patients with preserved or mildly reduced ejection fraction; ACE inhibitors remain the evidence‑based standard with proven mortality benefit, whereas sacubitril/valsartan lacks supporting data outside an ejection fraction ≤40 %. [12][13]